Sanara MedTech Inc.
SMTI Healthcare Medical Instruments & Supplies
Sanara MedTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $103.1 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 9.04%, EPS grew 78.3%, free cash flow grew 131.3% and total debt rose 5.11%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.
Follow SMTI
Sanara MedTech Inc. (SMTI) Piotroski F-score
Sanara MedTech Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 0.00 |
| FY2024 | 4 | 0.00 |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | (3.00) |
| FY2021 | 5 | 2.00 |
| FY2020 | 3 | 1.00 |
| FY2019 | 2 | (5.00) |
| FY2018 | 7 | 3.00 |
| FY2017 | 4 | (3.00) |
| FY2016 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (46.65%) | (11.93%) | Fail | 0 |
| Positive operating cash flow | 6.79m | (23.80k) | Pass | 1 |
| Rising return on assets | (46.65%) | (11.93%) | Fail | 0 |
| Cash flow above net income | 44.35m | 9.64m | Pass | 1 |
| Falling long-term leverage | 0.57 | 0.38 | Fail | 0 |
| Rising current ratio | 1.80 | 2.18 | Fail | 0 |
| No new shares issued | 8,623,000 | 8,484,000 | Fail | 0 |
| Rising gross margin | 92.71% | 90.61% | Pass | 1 |
| Rising asset turnover | 1.28 | 1.07 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| EMBC Embecta Corp. compare | 7 |
| UTMD Utah Medical Products, Inc. compare | 6 |
| PDEX Pro-Dex, Inc. compare | 6 |
| ANGO AngioDynamics, Inc. compare | 5 |
| NNNN Anbio Biotechnology compare | 5 |
| ZJYL Jin Medical International Ltd. compare | 4 |
| SMTI Sanara MedTech Inc. | 4 |
| OSUR OraSure Technologies, Inc. compare | 3 |
| AVR Anteris Technologies Global Corp. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover